Discover why Biogen's MS drug growth, robust margins, and Alcyone acquisition signal a 'Strong Buy.' Click here to read my ...

Cecelia Chen is a recipient of the Next Gen Leaders Recognition.As Director of Investments at Carnegie Corporation, Cecelia ...

Surgical procedures to repair the hand have historically been performed in the OR with patients receiving general ...

In its report this week, Glass Lewis largely sided with Broadwood’s assessment. The proxy advisor said STAAR’s board executed ...

Sintana Energy Inc. (TSX-V: SEI) ("Sintana" or the "Company") is pleased to announce that it has reached an agreement with Challenger Energy Group PLC ("Challenger") on the terms of an all-share ...

Value-based care promises improved outcomes for patients, healthcare providers, and health plans, and there is growing pressure for health systems ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

GSK plc’s strong oncology growth, highlighted by Ojjaara sales and an upgraded 2025 outlook, earns a continued 'Buy' rating.

Discover how XRP’s landmark legal win fueled Wall Street adoption, strengthening its position as a regulated, utility-driven ...

The more we’ve invested in past decisions, the more reluctant we are to bail out. But we can correct this bias by counting ...

The Department of Veterans Affairs spends billions on dubious and even fraudulent disabilities benefits. Meanwhile, some ...

Just about the only market consensus all year on next month's U.S. election was that it would be volatile around the vote - but even that's turning upside down three weeks before polling.